China National Accord Medicines Corporation Ltd. (SHE:000028)
China flag China · Delayed Price · Currency is CNY
21.09
-0.11 (-0.52%)
Nov 17, 2026, 3:04 PM CST

SHE:000028 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
72,72072,77873,67574,84472,70167,648
Other Revenue
637.52637.52703633.35742.57710.01
73,35773,41674,37875,47773,44368,358
Revenue Growth
0.44%-1.29%-1.46%2.77%7.44%14.60%
Cost of Revenue
65,77365,61866,18066,47164,56160,372
Gross Profit
7,5847,7978,1989,0068,8837,986
Selling, General & Admin
5,6105,8116,4076,4046,3745,772
Research & Development
8.4919.9924.5526.829.07-
Other Operating Expenses
195.73161.93116.393.73180.1139.09
Operating Expenses
5,8376,0776,6426,5966,5855,955
Operating Income
1,7471,7201,5562,4112,2982,031
Interest Expense
-160.43-194.5-258.3-248.38-261.91-288.04
Interest & Investment Income
211.77264.56300.32314.58212.07366.68
Currency Exchange Gain (Loss)
1.371.37-1.852.95-0.440.41
Other Non Operating Income (Expenses)
-35.85-43.62-28.62-27.9-1.89-4.87
EBT Excluding Unusual Items
1,7641,7481,5682,4522,2452,105
Impairment of Goodwill
-253.92-253.92-887.85--38.98-162.69
Gain (Loss) on Sale of Investments
-7.163.13-22.81-15.1628.87-
Gain (Loss) on Sale of Assets
-0.957.9611.8745.318.314.25
Asset Writedown
-43.94-31.84-84-0.64-18.87-75.55
Legal Settlements
-0.31-0.31-0.51-3.25-0.05-0.55
Other Unusual Items
50.4936-9.16-5.1286.36104.09
Pretax Income
1,5081,509575.472,4732,3111,975
Income Tax Expense
383.45380.67338.47514.74539.33447.21
Earnings From Continuing Operations
1,1251,1282371,9581,7721,528
Minority Interest in Earnings
6.47.58405.49-359.23-285.03-191.21
Net Income
1,1311,136642.491,5991,4871,336
Net Income to Common
1,1311,136642.491,5991,4871,336
Net Income Growth
111.83%76.80%-59.82%7.57%11.24%-4.67%
Shares Outstanding (Basic)
610612615613612612
Shares Outstanding (Diluted)
610612615613612612
Shares Change
-0.72%-0.38%0.26%0.12%--
EPS (Basic)
1.851.861.052.612.432.18
EPS (Diluted)
1.851.851.052.612.432.18
EPS Growth
113.27%77.38%-59.93%7.49%11.25%-4.59%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
1,4601,4212,9892,6152,2381,285
Free Cash Flow Per Share
2.392.324.864.273.662.10
Dividend Per Share
0.5600.5600.3330.6180.5590.420
Dividend Growth
68.32%68.32%-46.18%10.49%33.34%-24.99%
Gross Margin
10.34%10.62%11.02%11.93%12.09%11.68%
Operating Margin
2.38%2.34%2.09%3.19%3.13%2.97%
Profit Margin
1.54%1.55%0.86%2.12%2.02%1.96%
Free Cash Flow Margin
1.99%1.94%4.02%3.46%3.05%1.88%
EBITDA
959.291,9323,1023,8362,5422,239
EBITDA Margin
1.31%2.63%4.17%5.08%3.46%3.28%
D&A For EBITDA
-787.99212.011,5451,426244.32207.45
EBIT
1,7471,7201,5562,4112,2982,031
EBIT Margin
2.38%2.34%2.09%3.19%3.13%2.97%
Effective Tax Rate
25.42%25.23%58.82%20.81%23.34%22.64%
Revenue as Reported
73,35773,41674,37875,477--
Advertising Expenses
----46.6744.12